Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HIV Sales Fuel Gilead’s Robust First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech firm boasts record sales, record revenues.

You may also be interested in...



Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance

Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.

Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance

Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.

Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B

Company also awaits August PDUFA date for the same indication in the United States.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel